Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Status:
Completed
Trial end date:
2016-06-16
Target enrollment:
Participant gender:
Summary
This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0
mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis
IVA (Morquio A Syndrome).